

Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow

Patient ID SA00141384	Patient Name ATLAS REPORT, ABNORMAL	Birth Date 1990-01-01	Gender F	Age 31
Order Number SA00141384	Client Order Number SA00141384	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 12 Jan 2021 07:30		

MDS by Flow Cytometry, BM

Final Diagnosis

MCR

Bone marrow, flow cytometric immunophenotyping:

Cellular bone marrow specimen with increased myeloid lineage blasts, 6%.

Comment:

There is an increase in myeloid-lineage blasts that, by this analysis, are quantitatively insufficient to warrant an unequivocal diagnosis of acute myeloid leukemia. Blast cell percentages estimated by flow cytometry are affected by specimen processing and gating and, therefore, may differ significantly from those estimated by morphologic review. The differential diagnosis includes acute myeloid leukemia, a myelodysplastic syndrome, a myeloproliferative neoplasm, a mixed myelodysplastic/myeloproliferative neoplasm, treated or recurrent acute leukemia or other myeloid neoplasms, or sampling bias.

Correlation of the flow cytometry results with the bone marrow aspirate and biopsy findings, clinical history and other laboratory features is required for a definitive diagnosis. If desired, we can provide diagnostic services as part of a hematopathology consultation. Please contact the signing pathologist at 1-800-533-1710 if you have further questions regarding these analyses.

Reviewed by: SHANDA VOELTZ

Special Studies

MCR

%Lymphs: 10%

Results:

Blasts: Increased by CD45/side scatter and CD34.

Myeloid maturation:

HLA-DR/CD13 pattern on blasts: Abnormal CD13/CD16 pattern on maturing granulocytes: Abnormal CD2/CD7/CD56 expression on blasts: Abnormal expression of CD2, CD7, and CD56.

Additional markers tested: CD15, CD33, CD36, CD38, CD64, CD117.

B-cells: No monotypic; normal expression pattern of CD19, CD10, surface kappa and lambda.

T-cells/NK-cells: No aberrant phenotype by CD3 and CD16.

Quality assessment: Specimen received within validated guidelines.

Microscopic Description

MCR

A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.

MDS Panel

MCR

Performed

Received: 12 Jan 2021 13:13

Reported: 12 Jan 2021 14:39

Laboratory Notes

- 1 This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292